Alejandro Zaffaroni, founder of Syntex Corp., Alza Corp., DNAX Ltd. and Affymax N.V., which was just sold to Glaxo plc for $533 million, is in no hurry to do it all again. But he does have a vision of the hot areas in biotech and how others in the industry should go forward with new startup companies, which he shared with BioCentury last week. The following recounts his Commentary on the future.

To determine the direction of the industry, Alejandro Zaffaroni says one first must understand how the pharmaceutical industry historically has developed drugs, and recognize the bottlenecks in that process.